InsightAce Analytic 市場研究報告
主要涵蓋產業
最新報告
- Actinium-225 (Ac-225) MarketHealthcare & Life Sciences ・ 2026-09-16 ・ $4,500 USD
The actinium-225 market covers the production, purification and commercial supply of the alpha-emitting radionuclide Ac-225 used to label targeted alpha therapies, together with the associated radiochemical grades, shipp
- Lutetium-177 (Lu-177) MarketHealthcare & Life Sciences ・ 2026-09-16 ・ $4,500 USD
The lutetium-177 market comprises the production and supply of the beta-emitting radionuclide Lu-177 in carrier-added and non-carrier-added grades, plus the finished Lu-177-labelled radioligand therapies administered in
- Lead-212 (Pb-212) Targeted Alpha Therapy MarketHealthcare & Life Sciences ・ 2026-09-16 ・ $4,500 USD
The lead-212 targeted alpha therapy market covers Pb-212 isotope production and generator systems, the radioligand therapies that use Pb-212 as an in-situ generator of the alpha emitter bismuth-212, and the radiochemistr
- Radiopharmaceutical CDMO/CMO Services MarketHealthcare & Life Sciences ・ 2026-09-16 ・ $4,500 USD
The radiopharmaceutical CDMO/CMO services market covers outsourced development and manufacturing of radiolabelled therapeutics and diagnostics, including radiochemistry process development, GMP radiolabelling and drug pr
- Nuclear Pharmacy Services MarketHealthcare & Life Sciences ・ 2026-09-16 ・ $4,500 USD
The nuclear pharmacy services market comprises centralised and hospital-affiliated radiopharmacies that compound, quality-control, dispense and deliver patient-specific doses of diagnostic and therapeutic radiopharmaceut
- Generic GLP-1 Drugs MarketHealthcare & Life Sciences ・ 2026-09-16 ・ $4,500 USD
The generic GLP-1 drugs market covers off-patent and follow-on versions of glucagon-like peptide-1 receptor agonists for type 2 diabetes and obesity, including generic liraglutide already launched in several markets and
- GLP-1 Multi-Agonist & Combination Therapies MarketHealthcare & Life Sciences ・ 2026-09-16 ・ $4,500 USD
The GLP-1 multi-agonist and combination therapies market comprises incretin-based medicines that act on GLP-1 together with GIP, glucagon or amylin receptors, whether as single unimolecular agonists or fixed-dose combina
- GLP-1 Peptide CDMO & Manufacturing Capacity MarketHealthcare & Life Sciences ・ 2026-09-16 ・ $4,500 USD
The GLP-1 peptide CDMO and manufacturing capacity market covers outsourced manufacturing services dedicated to GLP-1 and related incretin peptides, from active ingredient synthesis through formulation, sterile fill-finis
- Peptide CDMO MarketHealthcare & Life Sciences ・ 2026-09-16 ・ $4,500 USD
The peptide CDMO market comprises contract development and manufacturing services for therapeutic peptides across all therapeutic areas, covering process development, GMP active ingredient production by solid-phase, liqu
- Antibody-Drug Conjugate (ADC) CDMO MarketHealthcare & Life Sciences ・ 2026-09-16 ・ $4,500 USD
The antibody-drug conjugate CDMO market covers outsourced development and manufacturing across the ADC value chain, including antibody production, cytotoxic payload and linker synthesis, bioconjugation, sterile fill-fini
- ADC Payload-Linker Manufacturing MarketHealthcare & Life Sciences ・ 2026-09-16 ・ $4,500 USD
The ADC payload-linker manufacturing market covers the synthesis and supply of cytotoxic and immunomodulatory payloads, linkers and pre-assembled drug-linker intermediates used to build antibody-drug conjugates, at both
- Next-Generation Drug Conjugates MarketHealthcare & Life Sciences ・ 2026-09-16 ・ $4,500 USD
The next-generation drug conjugates market covers targeted conjugate therapeutics that move beyond the classical monospecific antibody-cytotoxic ADC design, including bispecific and biparatopic ADCs, dual-payload ADCs, p